[Myeloid pseudo-splenomegaly in a patient with a myeloma].
BACKGROUND
Lymphoproliferative syndromes are rarely complicated by medullar fibrosis simulating myeloid splenomegaly.


METHODS
We report an unusual case of an IgD myeloma revealed in a context of myeloid splenomegaly in a 37 year-old man, initially admitted for severe anaemia associated with a voluminous splenomegaly.


CONCLUSIONS
The occurrence of myeloid splenomegaly during myeloma is extremely rare and only 14 cases have been reported. In this context, myelofibrosis is secondary to plasmocyte invasion of the bone marrow and regresses, or disappears, following specific treatment of the myeloma. The hypothesis evoked to explain the appearance of a secondary myelofibrosis is the "inappropriate" secretion, by the malignant plasmocyte clone, of functional analogs of pro-fibrosis cytokines, usually secreted by the mega-caryocyte precursors implied in myeloid splenomegaly.
Védrine
L
L
Service d'hématologie clinique, Hôpital d'instruction des armées Percy, Clamart, France. lmvt@wanadoo.fr
Boucher
E
E
Samson
T
T
Souleau
B
B
De Revel
T
T
Nedellec
G
G
D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001706:Biopsy; D001853:Bone Marrow / Q000000981:diagnostic imaging / Q000473:pathology; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy / Q000473:pathology*; D055728:Primary Myelofibrosis / Q000473:pathology*; D011877:Radionuclide Imaging; D012074:Remission Induction; D013163:Splenomegaly / Q000209:etiology / Q000473:pathology; D014750:Vincristine / Q000008:administration & dosage
D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D000972:Antineoplastic Agents, Phytogenic; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin